Protein ZMYND8 tied to suppression of prostate cancer tumor metastasis

July 28, 2016

Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center. The findings, resulting from cell line and mouse model studies, are published in the July 28 online issue of Molecular Cell.

"These findings are important as cancer metastasis is a complicated process and is both devastating and clinically challenging," said Min Gyu Lee, Ph.D., associate professor of Molecular and Cellular Oncology. "For metastasis, cancer cells acquire migratory and invasive abilities and so gaining new insight into how this occurs and how to stop metastasis is crucial. We believe this study opens a window into this process."

Lee's study centered on modification of proteins crucial to gene regulation, known as histones. Alterations in histone modifications, including acetylation and methylation, are frequently associated with development. Lee's group looked at ZMYND8 as a histone "reader" that could possibly impact by recognizing these known as histone "marks."

"It has been well documented that the effects of histone acetylation and methylation on gene expression can be mediated by specific binding proteins called 'readers,'" said Lee. "We identified ZMYND8 as a reader for histone marks called H3K4me1 and H3K14ac, both of which are tied to metastasis-linked genes."

The research group also noted that ZMYND8 cooperated with a type of histone mark "eraser" called JARID1D to suppress metastasis-linked genes.

"These findings are of special interest in light of our earlier study that JARID1D levels are lower in metastasized prostate tumors than in normal prostate and primary tumors," said Lee. "This study revealed a previously unknown metastasis-suppressive mechanism in which ZMYND8 counteracts the expression of metastasis-linked genes by reading dual histone marks H3K4me1 and H3K14ac and cooperating with JARID1D."

Explore further: Mouse model shows that Notch activation can drive metastatic prostate cancer

Related Stories

Mouse model shows that Notch activation can drive metastatic prostate cancer

June 13, 2016
Notch signaling is involved in prostate cancer and, in a paper published today in The Journal of Clinical Investigation, researchers from Baylor College of Medicine and other institutions have shown that, in a mouse model ...

Altered primary chromatin structures and their implications in cancer development

April 26, 2016
Cancer development is a complex process involving both genetic and epigenetic changes. Genetic changes in oncogenes and tumor-suppressor genes are generally considered as primary causes, since these genes may directly regulate ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.